|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Glimepiride,a new once-daily sulfonylurea:a double-blind placebo-controlled study of NIDDM patients显示文摘 | Rosenstock J Samols E Muchmore DB | 1996 | Diabetes Care1996，19，11： | 1 |
| 2 | Glimepiride,anew,once-dailysul-fonylurea:adouble-blind,placebo-controlled study of NIDDM patients显示文摘 | Wolffenbuttel J Samols E Muchmore DB | 1996 | Diabeties Care1996，19，： | 1 |
| 3 | Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4alpha 显示文摘 | Yong J Kong X Martins Santos ME Aleman G Chaco E Liu GE Wu SY Samols D Hakimi P Chiang CM Hanson RW | 2009 | J Biol Chem2009，284，27： | 1 |
| 4 | The glimepiride Study Group A new one daily sulfonylurea; double bling, placebo controlled study of NIDDM, patients显示文摘 | Rosenstock J Samols E Muchmore DB | 1996 | Diabetes Care1996，19，： | 1 |
| 5 | Intra-islet regulation 显示文摘 | Samols E Stagner JI | 1988 | Am J Med1988，85，5： | 1 |
| 6 | Beta-alpha-delta pancreatic islet cellularperfusion in dogs显示文摘 | Stagner JI Samols E Bonner-Weir S | 1988 | Diabetes1988，37，12： | 1 |
| 7 | Retrograde perfusion as a model for testing the relative effects of glucose versus insulin on the A cell显示文摘 | Stagner JI Samols E | | 0，，3： | 1 |
| 8 | lnterpretation of the intravenous glucose test显示文摘 | Samols E Marks V | 1965 | La ncet1965，1，： | 1 |
| 9 | Glimepiride,a new once-daily sulfonylurea显示文摘 | Rosenstock J Samole E Muchmore D | 1996 | Diabetes Care1996，19，11： | 1 |
| 10 | Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination withtopotecan for the treatment of patients with advanced solid tumors: A phase I study显示文摘 | SAMOL J RANSON M SCOTT E | 2012 | Invest New Drugs2012，30，4： | 1 |
| 11 | Intra- islet insu- lin- glucagon- somatostatin relationships 显示文摘 | SAMOLS E BONNER- WEIR S WEIR G C | 1986 | Clin Endocrinol Metab1986，15，1： | 1 |
| 12 | Intra-islet cell-cell interactions andinsulin secretion显示文摘 | Samols E Stagner J I | 1996 | Diabetes Rev1996，4，： | 1 |
| 13 | A doubleblind placebo-controlled study of NIDDM patients 显示文摘 | Schneider J Samols E | 1996 | Diabetes Care1996，19，： | 1 |
| 14 | Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study 显示文摘 | Samol J Ranson M Scott E | 2012 | Invest New Drugs2012，30，： | 1 |
| 15 | The induction of capillary bed development by endothelial growth factor before islet transplantation may prevent islet ischemia显示文摘 | Stagner JI Samols E | 1990 | Transplant Proc1990，22，2： | 1 |
| 16 | Safety and tolerability of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZI32281) in combination with topotecan for the treatment of patients with ad- vanced solid tumors: A phase I study显示文摘 | Samol J Ranson M Scott E | 2012 | Invest New Drugs2012，30，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员